Versameb Announces Management Update

Dr Klaas Zuideveld appointed as Chief Executive Officer to accelerate the development of Versameb’s lead pipeline products

Co-founder Prof Friedrich Metzger assumes role of Chief Scientific Officer to focus on leveraging the unique VERSagile RNA platform in the drive to realize its broad potential

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, announces the appointment of Dr Klaas Zuideveld as Chief Executive Officer (CEO). Prof Friedrich Metzger will move back to the role of Chief Scientific Officer (CSO) to focus on developing Versameb’s innovative VERSagile RNA platform to enhance and combine therapeutic protein expression and cellular targeting, optimizing and tailoring first-in-class RNA therapeutics for hard to treat diseases.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...